[1] Bagley WH, Yang H, Shah KH. Rhabdomyolysis [J]. Internal and Emergency Medicine, 2007, 2(3): 210-218.
[2] Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians [J]. Crit Care, 2005, 9(2): 158-169.
[3] Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment [J]. Ochsner J, 2015, 15(1): 58-69.
[4] Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis [J]. Eur J Intern Med, 2007, 18(2): 90-100.
[5] Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice [J]. Crit Care, 2016, 20(1): 135.
[6] Stahl K, Rastelli E, Schoser B. A systematic review on the definition of rhabdomyolysis [J]. J Neurol, 2020, 267(4): 877-882.
[7] Doyle JF, Forni LG. Acute kidney injury: short-term and long-term effects [J]. Crit Care, 2016, 20(1): 188.
[8] Gupta A, Thorson P, Penmatsa KR, et al. Rhabdomyolysis: Revisited [J]. Ulster Med J, 2021, 90(2): 61-69.
[9] Hebert JF, Burfeind KG, Malinoski D, et al. Molecular Mechanisms of Rhabdomyolysis-Induced Kidney Injury: From Bench to Bedside [J]. Kidney Int Rep, 2023, 8(1): 17-29.
[10] Muratsu J, Sanada F, Koibuchi N, et al. Blocking Periostin Prevented Development of Inflammation in Rhabdomyolysis-Induced Acute Kidney Injury Mice Model [J]. Cells, 2022, 11(21).
[11] Qiao O, Wang X, Wang Y, et al. Ferroptosis in acute kidney injury following crush syndrome: A novel target for treatment [J]. J Adv Res, 2023, 54: 211-222.
[12] Gburek J, Birn H, Verroust PJ, et al. Renal uptake of myoglobin is mediated by the endocytic receptors megalin and cubilin [J]. Am J Physiol Renal Physiol, 2003, 285(3): F451-458.
[13] Erratum Regarding "Rhabdomyolysis-Associated Acute Kidney Injury" (Am J Kidney Dis. 2018;71[6]:xii-xiv) [J]. Am J Kidney Dis, 2018, 72(3): 468.
[14] Scharf C, Liebchen U, Paal M, et al. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis [J]. Critical Care, 2021, 25(1).
[15] Zeng X, Zhang L, Wu T, et al. Continuous renal replacement therapy (CRRT) for rhabdomyolysis [J]. Cochrane Database Syst Rev, 2014, (6): Cd008566.
[16] Burgess S. Rhabdomyolysis: An evidence-based approach [J]. J Intensive Care Soc, 2022, 23(4): 513-517.
[17] Naka T, Jones D, Baldwin I, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report [J]. Crit Care, 2005, 9(2): R90-95.
[18] Sorrentino SA, Kielstein JT, Lukasz A, et al. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis [J]. Crit Care Med, 2011, 39(1): 184-186.
[19] Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance [J]. Crit Care, 2005, 9(2): 141-142.
[20] Weidhase L, de Fallois J, Hau?ig E, et al. Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial [J]. Crit Care, 2020, 24(1): 644.
[21] Wolley M, Jardine M, Hutchison CA. Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules [J]. Clin J Am Soc Nephrol, 2018, 13(5): 805-814.
[22] Heyne N, Guthoff M, Krieger J, et al. High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series [J]. Nephron Clin Pract, 2012, 121(3-4): c159-164.
[23] Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia [J]. Crit Care Med, 2004, 32(3): 801-805.
[24] Dominik A, Stange J. Similarities, Differences, and Potential Synergies in the Mechanism of Action of Albumin Dialysis Using the MARS Albumin Dialysis Device and the CytoSorb Hemoperfusion Device in the Treatment of Liver Failure [J]. Blood Purif, 2021, 50(1): 119-128.
[25] Kuntsevich VI, Feinfeld DA, Audia PF, et al. In-vitro myoglobin clearance by a novel sorbent system [J]. Artif Cells Blood Substit Immobil Biotechnol, 2009, 37(1): 45-47.
[26] Albrecht F, Schunk S, Fuchs M, et al. Rapid and Effective Elimination of Myoglobin with CytoSorb? Hemoadsorber in Patients with Severe Rhabdomyolysis [J]. Blood Purif, 2024, 53(2): 88-95.
[27] Jerman A, Andonova M, Persic V, et al. Extracorporeal Removal of Myoglobin in Patients with Rhabdomyolysis and Acute Kidney Injury: Comparison of High and Medium Cut-Off Membrane and an Adsorber Cartridge [J]. Blood Purif, 2022, 51(11): 907-911.
[28] Hui WF, Hon KL, Lun KS, et al. Successful Treatment of Rhabdomyolysis-Associated Acute Kidney Injury with Haemoadsorption and Continuous Renal Replacement Therapy [J]. Case Rep Pediatr, 2021, 2021: 2148024.
[29] Rauch S, Borgato A, Gruber E, et al. Case Report: Prevention of Rhabdomyolysis-Associated Acute Kidney Injury by Extracorporeal Blood Purification With Cytosorb((R)) [J]. Front Pediatr, 2021, 9: 801807.
[30] Padiyar S, Deokar A, Birajdar S, et al. Cytosorb for Management of Acute Kidney Injury due to Rhabdomyolysis in a Child [J]. Indian Pediatr, 2019, 56(11): 974-976.
[31] Hui WF, Chan RWY, Wong CK, et al. The Sequential Use of Extracorporeal Cytokine Removal Devices in an Adolescent With COVID-19 Receiving Continuous Renal Replacement Therapy [J]. Asaio j, 2022, 68(12): e230-e234.
[32] Hui WF, Cheung WL, Chung FS, et al. The successful application of hemoadsorption for extracorporeal liver support in a child with acute liver failure [J]. Int J Artif Organs, 2022, 45(10): 878-882.
[33] Kousoulas L, Wittel U, Fichtner-Feigl S, et al. Hemoadsorption in a Case of Severe Septic Shock and Necrotizing Fasciitis Caused by Nontraumatic Renal Rupture due to Pyelonephritis with Obstructive Uropathy [J]. Case Rep Crit Care, 2018, 2018: 5248901.
[34] Moresco E, Rugg C, Strohle M, et al. Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb((R)))-A case report [J]. Clin Case Rep, 2022, 10(1): e05272.
[35] Dilken O, Ince C, van der Hoven B, et al. Successful Reduction of Creatine Kinase and Myoglobin Levels in Severe Rhabdomyolysis Using Extracorporeal Blood Purification (CytoSorb(R)) [J]. Blood Purif, 2020, 49(6): 743-747.
[36] Immohr MB, Lichtenberg A, Boeken U, et al. Succesful treatment of a severe case of rhabdomyolysis following heart transplantation by hemoadsorption [J]. J Card Surg, 2020, 35(4): 940-941.
[37] Suefke S, Sayk F, Nitschke M. Hemoadsorption in Infection-Associated Rhabdomyolysis [J]. Ther Apher Dial, 2016, 20(5): 531-533.
[38] Wiegele M, Krenn CG. Cytosorb in a patient with Legionella pneumonia-associated rhabdomyolysis: a case report [J]. ASAIO J, 2015, 61(3): e14-16.
[39] Lang CN, Sommer MJ, Neukamm MA, et al. Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study [J]. Intensive Care Med Exp, 2020, 8(1): 21.
[40] Efstratiadis G, Voulgaridou A, Nikiforou D, et al. Rhabdomyolysis updated [J]. Hippokratia, 2007, 11(3): 129-137.
[41] Cabral BMI, Edding SN, Portocarrero JP, et al. Rhabdomyolysis [J]. Dis Mon, 2020, 66(8): 101015.
